About: Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Creator	Zhang, Xue Zhang, Hui Huang, Feng Li, Qianwen Pan, Ting Zhang, Junsong Bai, Chuan Liu, Chao Peng, Tao Tao, Liang Zhang, Jianhua Zhou, Nan
Source	Medline; PMC
abstract	Ebola virus infection can cause severe hemorrhagic fever with a high mortality in humans. The outbreaks of Ebola viruses in 2014 represented the most serious Ebola epidemics in history and greatly threatened public health worldwide. The development of additional effective anti-Ebola therapeutic agents is therefore quite urgent. In this study, via high throughput screening of Food and Drug Administration-approved drugs, we identified that teicoplanin, a glycopeptide antibiotic, potently prevents the entry of Ebola envelope pseudotyped viruses into the cytoplasm. Furthermore, teicoplanin also has an inhibitory effect on transcription- and replication-competent virus-like particles, with an IC(50) as low as 330 nm. Comparative analysis further demonstrated that teicoplanin is able to block the entry of Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) envelope pseudotyped viruses as well. Teicoplanin derivatives such as dalbavancin, oritavancin, and telavancin can also inhibit the entry of Ebola, MERS, and SARS viruses. Mechanistic studies showed that teicoplanin blocks Ebola virus entry by specifically inhibiting the activity of cathepsin L, opening a novel avenue for the development of additional glycopeptides as potential inhibitors of cathepsin L-dependent viruses. Notably, given that teicoplanin has routinely been used in the clinic with low toxicity, our work provides a promising prospect for the prophylaxis and treatment of Ebola, MERS, and SARS virus infection.
has issue date	2016-03-07(xsd:dateTime)
bibo:doi	10.1074/jbc.m116.716100
bibo:pmid	26953343
has license	bronze-oa
sha1sum (hex)	ebdc99b03d47e9b235e6b3f71a5032e5a4c221f0
schema:url	https://doi.org/10.1074/jbc.m116.716100
resource representing a document's title	Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
has PubMed Central identifier	PMC4861487
has PubMed identifier	26953343
schema:publication	Journal of Biological Chemistry
resource representing a document's body	covid:ebdc99b03d47e9b235e6b3f71a5032e5a4c221f0#body_text
is schema:about of	named entity 'severe acute respiratory syndrome (SARS)' named entity 'inhibiting' named entity 'severe' named entity 'high' named entity 'outbreaks' named entity 'study' named entity 'MERS' named entity 'telavancin' named entity 'Mechanistic' named entity 'GLYCOPEPTIDE ANTIBIOTICS' named entity 'EBOLA VIRUS' named entity 'VIRUS INFECTION' named entity 'MORTALITY' named entity 'TEICOPLANIN' named entity 'PREVENTS' named entity 'CAUSE' named entity 'MERS' named entity 'COMPARATIVE ANALYSIS' named entity 'GLYCOPEPTIDE ANTIBIOTIC' named entity 'EFFECTIVE' named entity 'INHIBITING' named entity 'SARS' named entity 'DRUGS' named entity 'STUDY' named entity 'VIRUS ENTRY' named entity 'APPROVED' named entity 'ENTRY' named entity 'SEVERE' named entity 'IDENTIFIED' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'ENTRY' named entity 'EBOLA VIRUS' named entity 'BLOCK' named entity 'CATHEPSIN L' named entity 'LATE ENDOSOME' named entity 'COMPETENT' named entity 'INHIBITORY EFFECT' named entity '330' named entity 'OUTBREAKS' named entity 'BLOCKS' named entity 'USED' named entity 'GREATLY' named entity 'HEMORRHAGIC FEVER' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'PROSPECT' named entity 'TREATMENT' named entity 'PROPHYLAXIS' named entity 'ADDITIONAL' named entity 'BLOCK' named entity 'EFFECT ON TRANSCRIPTION' named entity 'AVENUE' named entity 'VIRUS-LIKE PARTICLES' named entity 'EBOLA VIRUS INFECTION' named entity 'HUMANS' named entity 'NOVEL' named entity 'FOOD AND DRUG ADMINISTRATION' named entity 'MECHANISTIC STUDIES' named entity 'TELAVANCIN' named entity 'HIGH THROUGHPUT SCREENING' named entity 'VIRUSES' named entity 'OPENING' named entity 'EBOLA' named entity 'OUR' named entity 'THERAPEUTIC AGENTS' named entity 'CLINIC' named entity 'ORITAVANCIN' named entity 'ACTIVITY' named entity 'CATHEPSIN L' named entity 'HISTORY' named entity 'LOW'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software